Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.

about

Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo.

P2860

Q36337979-76BAC627-DBAA-48FC-8374-C1737840DA59

P2860

Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.

Item

http://www.wikidata.org/entity/Q45881290

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.

@en

Recombinant human prothrombin

@nl

type

Item

label

Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.

@en

Recombinant human prothrombin

@nl

prefLabel

Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.

@en

Recombinant human prothrombin

@nl

P1476

Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.

@en

P2093

A Lindblom

http://www.w3.org/2001/XMLSchema#string

A Lövgren

http://www.w3.org/2001/XMLSchema#string

K M Hansson

http://www.w3.org/2001/XMLSchema#string

M Elg

http://www.w3.org/2001/XMLSchema#string

P2860

A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

Novel, high incidence exercise-induced muscle bleeding model in hemophilia B mice: rationale, development and prophylactic intervention

FEIBA: mode of action.

A triple-transgenic immunotolerant mouse model.

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

History of rFVIIa therapy.

Characterization of thrombin derived from human recombinant prothrombin.

Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys.

Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.

P304

453-461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.12861

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26635073

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia A

hemophilia B

Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.

about

P2860

P2860

Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921